Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iris Yan

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
IEEE Pulse|January 19, 2012
Benefits of starting an EMBS student club/chapter at your universityIris Yan
IEEE Pulse|August 3, 2011
Another end…and a new beginning…Cristian A Linte, Iris Yan
International Journal of Rheumatic Diseases|January 3, 2026
Anti-Synthetase Syndrome-Advancing Disease Phenotyping, Classification and TreatmentIris Yan Ki Tang, Lijun Liu
JMA Journal|November 12, 2025
How the Cigarette Fire Burns the Rheumatoid JointsIris Yan Ki Tang, Chi Chiu Mok
Therapeutic Advances in Musculoskeletal Disease|July 24, 2023
Reduced bone mineral density in patients with idiopathic inflammatory myopathies: a case-control studyIris Yan Ki Tang, Lucas Luk, Victor Wong, et al.
Journal of Applied Clinical Medical Physics|January 20, 2022
A uniform and versatile surface-guided radiotherapy procedure and workflow for high-quality breast deep-inspiration breath-hold treatment in a multi-center institutionGuang Li, Wei Lu, Kyle O'Grady, et al.
NPJ Digital Medicine|May 4, 2026
Effective monitoring of online AI decision-making algorithms in just-in-time adaptive interventionsAnna L Trella, Susobhan Ghosh, Erin E Bonar, et al.
Rheumatology (Oxford, England)|September 17, 2024
Validation of the International Myositis Assessment and Clinical Studies Group guideline on cancer risk stratificationIris Yan Ki Tang, Shirley Chiu Wai Chan, Philip Hei Li, et al.
Rheumatology (Oxford, England)|December 14, 2023
Clinical heterogeneity and prognostic factors of anti-synthetase syndrome: a multi-centred retrospective cohort studyHoi San Tang, Iris Yan Ki Tang, Roy Tsz Chung Ho, et al.
Nature Medicine|May 16, 2025
Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trialCaicun Zhou, Xiaorong Dong, Gongyan Chen, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
IEEE Pulse|January 19, 2012
Benefits of starting an EMBS student club/chapter at your universityIris Yan
IEEE Pulse|August 3, 2011
Another end…and a new beginning…Cristian A Linte, Iris Yan
International Journal of Rheumatic Diseases|January 3, 2026
Anti-Synthetase Syndrome-Advancing Disease Phenotyping, Classification and TreatmentIris Yan Ki Tang, Lijun Liu
JMA Journal|November 12, 2025
How the Cigarette Fire Burns the Rheumatoid JointsIris Yan Ki Tang, Chi Chiu Mok
Therapeutic Advances in Musculoskeletal Disease|July 24, 2023
Reduced bone mineral density in patients with idiopathic inflammatory myopathies: a case-control studyIris Yan Ki Tang, Lucas Luk, Victor Wong, et al.
Journal of Applied Clinical Medical Physics|January 20, 2022
A uniform and versatile surface-guided radiotherapy procedure and workflow for high-quality breast deep-inspiration breath-hold treatment in a multi-center institutionGuang Li, Wei Lu, Kyle O'Grady, et al.
NPJ Digital Medicine|May 4, 2026
Effective monitoring of online AI decision-making algorithms in just-in-time adaptive interventionsAnna L Trella, Susobhan Ghosh, Erin E Bonar, et al.
Rheumatology (Oxford, England)|September 17, 2024
Validation of the International Myositis Assessment and Clinical Studies Group guideline on cancer risk stratificationIris Yan Ki Tang, Shirley Chiu Wai Chan, Philip Hei Li, et al.
Rheumatology (Oxford, England)|December 14, 2023
Clinical heterogeneity and prognostic factors of anti-synthetase syndrome: a multi-centred retrospective cohort studyHoi San Tang, Iris Yan Ki Tang, Roy Tsz Chung Ho, et al.
Nature Medicine|May 16, 2025
Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trialCaicun Zhou, Xiaorong Dong, Gongyan Chen, et al.
Pageof 2